DuoPlavin

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

clopidogrel, Acetylsalicylic acid

Disponible depuis:

Sanofi Winthrop Industrie

Code ATC:

B01AC30

DCI (Dénomination commune internationale):

clopidogrel, acetylsalicylic acid

Groupe thérapeutique:

Antithrombotic agents

Domaine thérapeutique:

Acute Coronary Syndrome; Myocardial Infarction

indications thérapeutiques:

DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in:Non ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (PCI);ST segment elevation acute myocardial infarction (STEMI) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.For further information please refer to section 5.1.

Descriptif du produit:

Revision: 30

Statut de autorisation:

Authorised

Date de l'autorisation:

2010-03-14

Notice patient

                                41
B. PACKAGE LEAFLET
42
PACKAGE LEAFLET: INFORMATION FOR THE USER
DUOPLAVIN 75 MG/75 MG FILM-COATED TABLETS
DUOPLAVIN 75 MG/100 MG FILM-COATED TABLETS
clopidogrel/acetylsalicylic acid
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What DuoPlavin is and what it is used for
2.
What you need to know before you take DuoPlavin
3.
How to take DuoPlavin
4.
Possible side effects
5
How to store DuoPlavin
6.
Contents of the pack and other information
1.
WHAT DUOPLAVIN IS AND WHAT IT IS USED FOR
DuoPlavin contains clopidogrel and acetylsalicylic acid (ASA) and
belongs to a group of medicines
called antiplatelet medicinal products. Platelets are very small
structures in the blood which clump
together during blood clotting. By preventing this clumping in some
types of blood vessels (called
arteries), antiplatelet medicinal products reduce the chances of blood
clots forming (a process called
atherothrombosis).
DuoPlavin is taken by adults to prevent blood clots forming in
hardened arteries which can lead to
atherothrombotic events (such as stroke, heart attack, or death).
You have been prescribed DuoPlavin in place of the two separate
medicines, clopidogrel and ASA, to
help prevent blood clots because you have experienced a severe type of
chest pain known as ‘unstable
angina’ or heart attack (myocardial infarction). For the treatment
of this condition your doctor may
have placed a stent in the blocked or narrowed artery to restore
effective blood flow.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DUOPLAV
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
DuoPlavin 75 mg/75 mg film-coated tablets
DuoPlavin 75 mg/100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
DuoPlavin 75 mg/75 mg film-coated tablets
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 75 mg of
acetylsalicylic acid (ASA).
_Excipients with known effect: _
Each film-coated tablet contains 7 mg of lactose and 3.3 mg of
hydrogenated castor oil.
DuoPlavin 75 mg/100 mg film-coated tablets
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 100 mg of
acetylsalicylic acid (ASA).
_Excipients with known effect: _
Each film-coated tablet contains 8 mg of lactose and 3.3 mg of
hydrogenated castor oil.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
DuoPlavin 75 mg/75 mg film-coated tablets
Yellow, oval, slightly biconvex, engraved with «C75» on one side and
«A75» on the other side.
DuoPlavin 75 mg/100 mg film-coated tablets
Light pink, oval, slightly biconvex, engraved with «C75» on one side
and «A100» on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
DuoPlavin is indicated for the secondary prevention of
atherothrombotic events in adult patients
already taking both clopidogrel and acetylsalicylic acid (ASA).
DuoPlavin is a fixed-dose combination
medicinal product for continuation of therapy in:
•
Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction) including patients undergoing a stent placement
following percutaneous
coronary intervention (PCI)
•
ST segment elevation acute myocardial infarction (STEMI) in patients
undergoing PCI
(including patients undergoing a stent placement) or medically treated
patients eligible for
thrombolytic/ fibrinolytic therapy
For further information please refer to section 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and elderly _
DuoPlavin 75 mg/75 mg film-coated ta
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 16-02-2023
Notice patient Notice patient espagnol 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 16-02-2023
Notice patient Notice patient tchèque 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 16-02-2023
Notice patient Notice patient danois 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation danois 16-02-2023
Notice patient Notice patient allemand 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 16-02-2023
Notice patient Notice patient estonien 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 16-02-2023
Notice patient Notice patient grec 07-07-2023
Notice patient Notice patient français 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation français 16-02-2023
Notice patient Notice patient italien 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation italien 16-02-2023
Notice patient Notice patient letton 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation letton 16-02-2023
Notice patient Notice patient lituanien 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 16-02-2023
Notice patient Notice patient hongrois 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 16-02-2023
Notice patient Notice patient maltais 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 16-02-2023
Notice patient Notice patient néerlandais 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 16-02-2023
Notice patient Notice patient polonais 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 16-02-2023
Notice patient Notice patient portugais 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 16-02-2023
Notice patient Notice patient roumain 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 16-02-2023
Notice patient Notice patient slovaque 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 16-02-2023
Notice patient Notice patient slovène 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 16-02-2023
Notice patient Notice patient finnois 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 16-02-2023
Notice patient Notice patient suédois 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 16-02-2023
Notice patient Notice patient norvégien 07-07-2023
Notice patient Notice patient islandais 07-07-2023
Notice patient Notice patient croate 07-07-2023
Rapport public d'évaluation Rapport public d'évaluation croate 16-02-2023

Rechercher des alertes liées à ce produit

Afficher l'historique des documents